Takeda reported that its oral TYK2 inhibitor zasocitinib (investigational) outperformed Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a head-to-head Phase 3 psoriasis program, showing statistical superiority across primary and key secondary endpoints. The results strengthen Takeda’s push to build a leadership position in the oral autoimmune market as competition intensifies. In parallel, Enliven Therapeutics updated Phase 1 data for ELVN-001 in previously treated CML, reporting that the proposed 80 mg go-forward cohort achieved major molecular response in 48% at 24 weeks, up from prior reporting. The company’s approach is directed at the BCR::ABL1 fusion and is positioned for a Phase 3 start expected in the second half of the year. Both updates add near-term decision pressure for development strategy: Takeda needs to translate comparative efficacy into patient uptake, while Enliven is using strengthened early molecular response to de-risk the transition to Phase 3.